What does gyre pharmaceuticals — transaction costs mean?

This captures the non-recurring expenses directly related to the execution of specific business transactions, such as acquisitions, divestitures, or strategic partnerships. Tracking these costs helps investors isolate the impact of one-time corporate activities from core operational performance.

Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Transaction Costs

Other segment segments

Gyre

$2.55M—

All Other Segments

$0—

Similar metrics at other companies

LFSTTransaction Costs

$544K—

EPRTransaction costs

$293K-48.3%

RMRTransaction and acquisition related costs

$227K-58.7%

NTSTTransaction costs, net

-$60K-228%

CARTransaction-related costs, net

$6M—

ASSTCorporate & Other — Transaction costs

$6.53M—

Other financials

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

EPS (diluted)-$0.10—

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation

See full

Market cap$694.58M-4.7%

Enterprise value$657.9M-8.0%

P/S5.9×-1.3×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

Net margin6.3%+3.3pp

FCF margin2.6%—

Returns & leverage

See full

Return on equity8.2%+4.2pp

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept gyre:TransactionCosts.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — transaction costs.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — transaction costs?: Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — transaction costs of $0 in Q1 2026.
What does gyre pharmaceuticals — transaction costs mean?: This captures the non-recurring expenses directly related to the execution of specific business transactions, such as acquisitions, divestitures, or strategic partnerships. Tracking these costs helps investors isolate the impact of one-time corporate activities from core operational performance.